This month’s issue – a double recommendation
7th March 2017 |
This month’s issue of Frontier Tech Investor is now live.
I think it’s our best yet. Though I’m clearly biased, given I’m the publisher.
This month, which also coincidentally marks a year of tech analysis, opportunity and insight, we focus on one of the biggest themes in the tech world today: gene editing.
I think gene editing in general, and CRISPR specifically, may well become the most important technology of the 21st century. There’s already vast amounts of capital flowing into the industry. Today we join the likes of Bill Gates and Google Ventures in claiming our own stake.
It’s such an important sector that we’re introducing two ways of playing it. One is a company at the very heart of the burgeoning industry, with patents that could be worth a fortune. The other is an AIM listed firm that plays a vital role in genetic research and development.
On top of that we have a rundown of the top ten UK listed genetics firms, plus three exclusive interviews with industry insiders. It’s a bumper issue!
You can view it now by following this link.
Best,
Nick O’Connor
Publisher, Frontier Tech Investor
PS I’ve received a few notes regarding our cannabis play, TerraTech. These are exciting times with cannabis moving towards legalisation. It’s clearly a US story which can lead to difficulties buying shares here in the UK. Whilst we don’t recommend specific brokers, my suggestion is you try Interactive Investor, AJ Bell or Hargreaves Lansdown. You may need to call them directly to arrange a purchase. I know it can be frustrating. But we want to bring you the very best investment opportunities the world has to offer – and the legalisation of cannabis in the US is certainly one of them.